Detail of "71620-89-8"

Reference

Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine

Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine. Fava, Maurizio; McGrath, Patrick J.; Sheu, Wang-Pui (Massachusetts General Hospital, Boston, MA, USA). Journal of Clinical Psychopharmacology, 23(4), 365-369 (English) 2003 Lippincott Williams & Wilkins. CODEN: JCPYDR. ISSN: 0271-0749. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The aim of the present study was to evaluate the efficacy and safety of an immediate switch to reboxetine, a selective noradrenaline reuptake inhibitor (selective NRI), in patients with depression unresponsive to the selective serotonin reuptake inhibitor (SSRI) fluoxetine. The study included 128 adult outpatients with DSM-IV major depressive disorder (MDD) who had not responded to at least 6 to 12 wk of fluoxetine treatment, with at least 3 wk of treatment on a min. dose of 40 mg/d. Patients were switched, without a washout period, to reboxetine 4 mg twice daily, with the possibility of increasing the dose to 10 mg/d (given in divided doses) after 4 wk of treatment. Efficacy was assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and the Clin. Global Impression Improvement (CGI-I) and Severity (CGI-S) scales. Safety was evaluated by recording spontaneously reported adverse events. A statistically significant (P < 0.There are some commonly used reagents with their cas registry numbers 71620-89-8 and 54910-89-3 in this article.001) improvement in the mean total HAM-D-17 score was seen from baseline by week 1 of treatment with reboxetine, and the improvement continue to week 8. CGI-I and CGI-S scores were similarly improved. The switch to reboxetine was well tolerated; the most common treatment-emergent adverse events were insomnia, headache, dry mouth, diaphoresis, and constipation, all of which were mild to moderate in severity and decreased in frequency as the study progressed. Immediate switching to reboxetine appears to be a safe and effective treatment for patients with depression who have failed to respond to an adequate dose of fluoxetine. .

The Effects of Norepinephrine Transporter Inactivation on Locomotor Activity in Mice

All Rights Reserved. The Effects of Norepinephrine Transporter Inactivation on Locomotor Activity in Mice. Mitchell, Heather A.; Ahern, Todd H.; Liles, L. Cameron; Javors, Martin A.; Weinshenker, David (Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA).Some commonly used reagents like 34911-55-2 and 71620-89-8 are used in this experiment. Biological Psychiatry, 60(10), 1046-1052 (English) 2006 Elsevier Inc. CODEN: BIPCBF. ISSN: 0006-3223. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: Acute administration of different classes of antidepressants can enhance or reduce spontaneous locomotor activity in a novel environment, but the effects of chronic antidepressant treatment on spontaneous locomotor activity in novel and familiar environments are less well characterized. Because norepinephrine is an important regulator of spontaneous locomotor activity, we speculated that norepinephrine transporter blockade contributes to the effects of some antidepressants on spontaneous locomotor activity. Methods: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (i.p.) or chronically (via osmotic minipump) to control and norepinephrine transporter knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded. Results: Acute treatment with most norepinephrine transporter-blocking antidepressants decreased spontaneous locomotor activity in a novel environment, whereas chronic treatment decreased spontaneous locomotor activity in both novel and familiar environments. The exception was bupropion, a dual norepinephrine transporter/dopamine transporter blocker, which tended to increase spontaneous locomotor activity. Coadministration of reboxetine and the dopamine transporter blocker GBR 12909 also increased spontaneous locomotor activity. Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in norepinephrine transporter knockout mice. Conclusions: Acute or chronic inactivation of the norepinephrine transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with dopamine transporter blockade. .